Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0, His Tag (MALS verified)

Catalog # RSF-V52H4



Synonym

Fusion glycoprotein F0

Source

Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0, His Tag(RSF-V52H4) is expressed from human 293 cells (HEK293). It contains AA Val 20 - ILe 486(FAGIAIGIA 103-111del) (Accession # <u>P11236</u> (FAGIAIGIA 103-111del)).

Predicted N-terminus: Val 20

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 51.9 kDa. The protein migrates as 53-63 kDa when calibrated against <u>Star Ribbon Pre-stained Protein Marker</u> under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μ m filtered solution in PBS with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With <u>Star</u> <u>Ribbon Pre-stained Protein Marker</u>).

SEC-MALS



The purity of Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H4) is more than 85% and the molecular weight of this protein is around 185-215 kDa verified by SEC-MALS. Report

Background

Mumps immunity is typically assessed by measuring neutralizing-antibody responses directed against mumps HN and F proteins.

Clinical and Translational Updates



Catalog # RSF-V52H4



Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.



>>> www.acrobiosystems.com

